IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors - PubMed (original) (raw)
Simona Lamba, Sieger Leenstra, Dirk Troost, Theo Hulsebos, W Peter Vandertop, Milo Frattini, Francesca Molinari, Margaret Knowles, Aniello Cerrato, Monica Rodolfo, Aldo Scarpa, Lara Felicioni, Fiamma Buttitta, Sara Malatesta, Antonio Marchetti, Alberto Bardelli
Affiliations
- PMID: 19117336
- DOI: 10.1002/humu.20937
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors
Fonnet E Bleeker et al. Hum Mutat. 2009 Jan.
Abstract
Systematic sequence profiling of the Glioblastoma Multiforme (GBM) genome has recently led to the identification of somatic mutations in the isocitrate dehydrogenase 1 (IDH1) gene. Interestingly, only the evolutionarily conserved residue R132 located in the substrate binding site of IDH1 was found mutated in GBM. At present, the occurrence and the relevance of p.R132 (IDH1(R132)) variants in tumors other than GBMs is largely unknown. We searched for mutations at position R132 of the IDH1 gene in a panel of 672 tumor samples. These included high-grade glioma, gastrointestinal stromal tumors (GIST), melanoma, bladder, breast, colorectal, lung, ovarian, pancreas, prostate, and thyroid carcinoma specimens. In addition, we assessed a panel of 84 cell lines from different tumor lineages. Somatic mutations affecting the IDH1(R132) residue were detected in 20% (23 of 113) high-grade glioma samples. In addition to the previously reported p.R132H and p.R132S alleles, we identified three novel somatic mutations (p.R132C, p.R132G, and p.R132L) affecting residue IDH1(R132) in GBM. Strikingly, no IDH1 mutations were detected in the other tumor types. These data indicate that cancer mutations affecting IDH1(R132) are tissue-specific, and suggest that it plays a unique role in the development of high-grade gliomas.
Copyright 2008 Wiley-Liss, Inc.
Similar articles
- Analysis of the IDH1 codon 132 mutation in brain tumors.
Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Balss J, et al. Acta Neuropathol. 2008 Dec;116(6):597-602. doi: 10.1007/s00401-008-0455-2. Epub 2008 Nov 5. Acta Neuropathol. 2008. PMID: 18985363 - Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A. Hartmann C, et al. Acta Neuropathol. 2009 Oct;118(4):469-74. doi: 10.1007/s00401-009-0561-9. Epub 2009 Jun 25. Acta Neuropathol. 2009. PMID: 19554337 - Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
Gravendeel LA, Kloosterhof NK, Bralten LB, van Marion R, Dubbink HJ, Dinjens W, Bleeker FE, Hoogenraad CC, Michiels E, Kros JM, van den Bent M, Smitt PA, French PJ. Gravendeel LA, et al. Hum Mutat. 2010 Mar;31(3):E1186-99. doi: 10.1002/humu.21201. Hum Mutat. 2010. PMID: 20077503 - IDH mutations in glioma and acute myeloid leukemia.
Dang L, Jin S, Su SM. Dang L, et al. Trends Mol Med. 2010 Sep;16(9):387-97. doi: 10.1016/j.molmed.2010.07.002. Epub 2010 Aug 5. Trends Mol Med. 2010. PMID: 20692206 Review. - Role of isocitrate dehydrogenase in glioma.
Alexander BM, Mehta MP. Alexander BM, et al. Expert Rev Neurother. 2011 Oct;11(10):1399-409. doi: 10.1586/ern.11.134. Expert Rev Neurother. 2011. PMID: 21955197 Review.
Cited by
- Gliomagenesis, Epileptogenesis, and Remodeling of Neural Circuits: Relevance for Novel Treatment Strategies in Low- and High-Grade Gliomas.
Grimi A, Bono BC, Lazzarin SM, Marcheselli S, Pessina F, Riva M. Grimi A, et al. Int J Mol Sci. 2024 Aug 16;25(16):8953. doi: 10.3390/ijms25168953. Int J Mol Sci. 2024. PMID: 39201639 Free PMC article. Review. - Research hotspots and trend of glioblastoma immunotherapy: a bibliometric and visual analysis.
Lv K, Du X, Chen C, Yu Y. Lv K, et al. Front Oncol. 2024 Aug 7;14:1361530. doi: 10.3389/fonc.2024.1361530. eCollection 2024. Front Oncol. 2024. PMID: 39175478 Free PMC article. - Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives.
Carosi F, Broseghini E, Fabbri L, Corradi G, Gili R, Forte V, Roncarati R, Filippini DM, Ferracin M. Carosi F, et al. Cancers (Basel). 2024 Aug 2;16(15):2752. doi: 10.3390/cancers16152752. Cancers (Basel). 2024. PMID: 39123479 Free PMC article. Review. - Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma.
Richardson TE, Walker JM, Hambardzumyan D, Brem S, Hatanpaa KJ, Viapiano MS, Pai B, Umphlett M, Becher OJ, Snuderl M, McBrayer SK, Abdullah KG, Tsankova NM. Richardson TE, et al. Acta Neuropathol. 2024 Jul 16;148(1):5. doi: 10.1007/s00401-024-02761-7. Acta Neuropathol. 2024. PMID: 39012509 Free PMC article. Review. - idh-1 neomorphic mutation confers sensitivity to vitamin B12 in Caenorhabditis elegans.
Ponomarova O, Starbard AN, Belfi A, Anderson AV, Sundaram MV, Walhout AJ. Ponomarova O, et al. Life Sci Alliance. 2024 Jul 15;7(10):e202402924. doi: 10.26508/lsa.202402924. Print 2024 Oct. Life Sci Alliance. 2024. PMID: 39009411 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous